Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Total Liabilities
Everything the company owes to creditors and other parties.
Viking Therapeutics, Inc.NASDAQ: VKTX
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 250.7% from a year ago
Total liabilities stood at $113.58M at the end of Q2 FY2026, up 250.7% from a year earlier and up 6.8% from the prior quarter. Over 3 fiscal years it compounded at +48.9% a year.
Context
- Total liabilities amounted to 21.8% of total assets at the end of Q2 FY2026, up 17.9 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +250.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 76.67M USD
- Year-over-year change
- +173.4%
- 4-year CAGR
- +71.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 76.67M | +173.4% |
| FY2024 | 2024-12-31 | 28.04M | +39.7% |
| FY2023 | 2023-12-31 | 20.07M | -13.5% |
| FY2022 | 2022-12-31 | 23.21M | +164.4% |
| FY2021 | 2021-12-31 | 8.78M | — |
Total Liabilities vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's Jun 2026 total liabilities of $113.58M is the 3rd highest of the 7 companies compared; the peer median is $82.99M.
- Its year-over-year change of +250.7% is the highest of 6, against a peer median of +99.5%.
- Total liabilities amounts to 21.8% of total assets for VKTX, versus a peer median of 9.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $720.92M | +125.7% | +58.4% | 57.9% | |
SEPNSepterna, Inc. | Sep 2026 | $191.48M | -12.1% | +38.7% | 30.9% |
| Jun 2026 | $113.58M | +250.7% | +48.9% | 21.8% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $92.95M | — | — | 7.7% |
| Jun 2026 | $73.03M | +99.5% | +21.0% | 10.4% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $27.67M | +120.7% | -43.4% | 5.5% |
| Mar 2026 | $8.85M | -61.7% | -2.4% | 9.0% | |
| Peer median (excluding VKTX) | $82.99M | +99.5% | +21.0% | 9.7% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 26.37M | 36.63M | 55.52M | 26.68M | 165.81M |
| Short-term Investments | 175.73M | 118.85M | 306.56M | 875.94M | 539.93M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 7.81M | 8.14M | 2.52M | 1.13M | 1.81M |
| Total Current Assets | 210.53M | 167.04M | 367.23M | 907.22M | 715.6M |
| Property, Plant & Equipment (Net) | 25K | 1.42M | 1.13M | 1M | 85K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 109K | 71K | 139K | 102K | 46K |
| Total Non-current Assets | 134K | 1.49M | 1.27M | 1.11M | 131K |
| Total Assets | 210.66M | 168.53M | 368.49M | 908.32M | 715.73M |
| Account Payables | 1.44M | 8.53M | 7.51M | 9.81M | 53.25M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 8.78M | 21.95M | 19.14M | 27.41M | 76.67M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 1.26M | 936K | 630K | 0 |
| Total Liabilities | 8.78M | 23.21M | 20.07M | 28.04M | 76.67M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | (223.18M) | (292.05M) | (377.94M) | (487.91M) | (847.55M) |
| Accumulated OCI | (549K) | (1.1M) | (389K) | (788K) | 378K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 201.88M | 145.32M | 348.42M | 880.28M | 639.06M |
| Total Debt | 29K | 1.56M | 1.26M | 1.12M | 137K |
| Net Debt | (26.34M) | (35.07M) | (54.26M) | (25.56M) | (165.67M) |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.